Immunotherapy, the use of the body's immune system to fight cancer, has revolutionized oncology. This article presents a comprehensive guide to understanding the mechanisms, applications, and implications of immunotherapy.
Immunotherapy represents a paradigm shift from traditional cancer treatments. Instead of directly targeting cancer cells, it manipulates the immune system to recognize and destroy them. The two main types are checkpoint inhibitors and CAR-T cell therapy. Checkpoint inhibitors block proteins that prevent immune cells from attacking cancer, while CAR-T cell therapy involves genetically modifying a patient's T cells to target cancer cells.
Immunotherapy has shown efficacy in various cancers, including melanoma, lung, and kidney cancers. It is also being explored in hematological malignancies. However, its effectiveness varies among patients due to factors such as genetic makeup and tumor microenvironment. Biomarkers like PD-L1 expression and tumor mutational burden can predict response to immunotherapy.
Immunotherapy can cause immune-related adverse events (irAEs), which can affect any organ system. Management strategies include corticosteroids and other immunosuppressants. It is essential for physicians to recognize and manage these side effects promptly to prevent severe complications.
The future of immunotherapy lies in combinatorial approaches, personalized medicine, and understanding resistance mechanisms. Ongoing research aims to identify new targets, develop more effective CAR-T cells, and understand why some patients do not respond to treatment.
Immunotherapy has transformed cancer treatment, offering hope to many patients. However, it also poses unique challenges in terms of predicting response, managing side effects, and understanding resistance. As we continue to decode immunotherapy, physicians must stay updated to provide optimal care to their patients.
1.
Tumor characteristics found to differ for melanomas in children, teens and young adults
2.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
3.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
4.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
2.
Screening for Early Therapy-Related Cancer Susceptibility
3.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
4.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
5.
Reducing Modifiable Childhood Cancer Exposure Risks
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Importance of Cancer Screening and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation